奥美沙坦对高血压患者的疗效及心血管病危险因素的影响  

Therapeutic effect of olmesartan on essential hypertension and its influence on cardiovascular risk factors

作　　者：林泽鹏[1] 孙晓红[1] 张志伟[1] 

机构地区：[1]深圳市孙逸仙心血管医院急诊科,广东深圳518020

出　　处：《心血管康复医学杂志》2015年第3期310-312,共3页Chinese Journal of Cardiovascular Rehabilitation Medicine

摘　　要：目的：评价奥美沙坦对轻、中度原发性高血压患者的疗效及心血管病危险因素的影响。方法：采用开放非对照、多中心的方法,本研究入选原发性轻/中度高血压患者150例,按随机数字表法（1∶1）被随机分配到奥美沙坦（口服20-40mg/d）组或氯沙坦（口服50-100mg/d）组,观察治疗前后收缩压、舒张压、心血管病危险指标高敏C反应蛋白（hsCRP）、尿白蛋白/肌酐、同型半胱氨酸（Hcy）水平及颈动脉内膜中层厚度（IMT）的变化。结果：两组治疗8个月后各指标较治疗前均有明显改善;与氯沙坦组比较,奥美沙坦组收缩压[（145±12）mmHg比（132±9）mmHg]、舒张压[（90±7）mmHg比（80±5）mmHg]下降更显著（P均〈0.01）;hsCRP[（0.54±0.09）mg/L比（0.34±0.09）mg/L]、尿白蛋白/肌酐[（26.5±19.4）mg/g比（23.1±18.3）mg/g]、Hcy[（13.2±4.8）μmol/L比（10.3±4.2）μmol/L]水平及IMT[（0.83±0.29）mm比（0.74±0.28）mm]显著下降（P均〈0.05）。结论：对于轻中度高血压患者,奥美沙坦除强效降压外,还能明显降低心血管病危险因素。Objective：To evaluate therapeutic effect of olmesartan on patients with mild to moderate essential hyper-tension （EH） and its influence on cardiovascular risk factors .Methods：A total of 150 mild/moderate EH patients were enrolled using opened ,non-control and multi-center method .According to random number table ,they were randomly and equally divided into olmesartan group （received olmesartan 20-40 mg/d） and losartan group （re-ceived losartan 50-100 mg/d） .Changes of systolic blood pressure （SBP） ,diastolic blood pressure （DBP） , levels of risk indexes of cardiovascular diseases ,such as high sensitive C reactive protein （hsCRP） ,urinary albumin/creati-nine ,homocysteine （Hcy） and carotid intima-media thickness （IMT） were observed in two groups before and after treatment .Results：After eight-month treatment , compared with before treatment , all indexes significantly im-proved in both groups;compared with losartan group ,there were significant reductions in SBP [ （145 ± 12） mmHg vs .（132 ± 9） mmHg] and DBP [ （90 ± 7） mmHg vs .（80 ± 5） mmHg] , P〈0.01 all;and significant reductions in levels of hsCRP [ （0.54 ± 0.09） mg/L vs .（0.34 ± 0.09） mg/L] ,urinary albumin/creatinine [ （26.5 ± 19.4） mg/g vs .（23.1 ± 18.3） mg/g] ,Hcy [ （13.2 ± 4.8）μmol/L vs .（10.3 ± 4.2）μmol/L] and IMT [ （0.83 ± 0.29） mm vs . （0.74 ± 0.28） mm] in olmesartan group , P〈 0.05 all .Conclusion：Besides intensively lowering blood pressure olmesartan can also significantly decrease cardiovascular risk factors in patients with mild to moderate hypertension .

关 键 词：高血压 C反应蛋白质 半胱氨酸 奥美沙坦 

分 类 号：R544.1[医药卫生—心血管疾病]